Denovo Biopharma has secured approval from the US Food and Drug Administration (FDA) to begin a Phase IIb clinical trial of DB104 (liafensine) in individuals with treatment-resistant depression (TRD).

The trial will analyse the safety and efficacy of liafensine in TRD patients. Denovo noted that it will be the third potentially pivotal international trial to be carried out by the company and the first-ever genetic biomarker-guided trial for diseases of the central nervous system (CNS).

Denovo Biopharma chief technical officer Xiao-Xiong Lu said: “CNS diseases are notoriously difficult to treat, and lack of precision medicines may contribute to the modest success in developing innovative drugs in this area.

“Denovo used its unique biomarker platform to identify a novel predictive biomarker named Denovo Genomic Marker 4 (DGM4), which is highly associated with clinical response to liafensine in patients with TRD.”

Developed initially by AMRI, liafensine was licenced to Bristol-Myers Squibb (BMS). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Later, Denovo gained worldwide rights to the drug, which comprise research and development, manufacturing and supply. 

In various Phase II trials carried out by BMS, liafensine demonstrated increased tolerance in TRD patients. 

Nearly one-third of the major depressive disorder patients do not respond well to a minimum of two distinct antidepressants of sufficient dose and time in the present depressive episode and are classified as having TRD.

Currently, Denovo’s pipeline includes eight late clinical-stage drugs intended to address key unmet medical needs in oncology and CNS diseases.

The company’s trial for its lead asset DB102 (enzastaurin) has concluded enrolment of subjects with diffuse large B-cell lymphoma in a Phase III trial in the US and China while enrolment is underway in a Phase III glioblastoma trial.